AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Teladoc Exceeds Q2 Revenue Expectations, Sets New FY22 Guidance
ByAinvest
Tuesday, Jul 29, 2025 4:49 pm ET1min read
Teladoc Health (TDOC) reported Q2 CY2025 results exceeding revenue expectations, with sales of $631.9 million, a 1.6% YoY decline. The company's GAAP loss of $0.19 per share was 27.8% above analysts' consensus estimates. Teladoc slightly lifted its revenue guidance for the full year to $2.52 billion at the midpoint and expects a GAAP loss of $1.18 per share.
Teladoc Health Inc. (NYSE: TDOC) reported its second-quarter (Q2) 2025 financial results, revealing a 1.6% year-over-year (YoY) decline in revenue to $631.9 million, which exceeded analysts' expectations [1]. The company's GAAP loss of $0.19 per share was 27.8% above the consensus estimate of $0.26 per share, driven by a 4% YoY increase in the Integrated Care segment and a 9% YoY decline in the BetterHelp segment [2].The company's adjusted EBITDA, a measure of operating profitability, fell 23% to $69.3 million, but this was also above the consensus estimate of $63.50 million [1]. Teladoc attributed the revenue decline primarily to challenges in its direct-to-consumer market segment, BetterHelp, which saw a 9% YoY decrease in revenue to $240.4 million [2].
Teladoc's CEO, Chuck Divita, expressed satisfaction with the company's performance, stating that the results reflect "continued disciplined execution and builds on our solid results from the first quarter" [2]. The company also secured a $300 million credit facility to enhance financial flexibility [1].
For the third quarter (Q3) 2025, Teladoc expects revenue between $614 million and $636 million, with a GAAP loss of $0.20 to $0.35 per share. The full-year 2025 revenue guidance was lifted to $2.52 billion at the midpoint, with a GAAP loss of $1.18 per share [2].
Analysts remain cautiously optimistic, with an average rating of "hold" and a breakdown of recommendations including 5 "strong buy" or "buy," 22 "hold," and no "sell" or "strong sell" [1]. The median 12-month price target for Teladoc Health Inc. stands at $8.38, about 2.1% above its July 28 closing price of $8.20 [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX9CB307:0-teladoc-q2-revenue-down-2-but-beats-expectations/
[2] https://www.investing.com/news/earnings/teladoc-shares-jump-6-on-narrower-than-feared-q2-loss-revenue-beats-93CH-4158464
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet